SAB BIOTHERAPEUTICS, INC. Payments for (Proceeds from) Investments
SAB BIOTHERAPEUTICS, INC. (SABS) reported Payments for (Proceeds from) Investments of $116.15 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromInvestments · last filed 2021-11-22
- SAB BIOTHERAPEUTICS, INC. payments for (proceeds from) investments for the quarter ending 2021-09-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. payments for (proceeds from) investments for the quarter ending 2021-06-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. payments for (proceeds from) investments for the quarter ending 2021-03-31 was $116.15M.
| Period end | Payments for (Proceeds from) Investments 3 month | Payments for (Proceeds from) Investments 6 month | Payments for (Proceeds from) Investments 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22 | $0.00 derived: sum of 2 quarters · filed 2021-11-22 | $116.15M 10-Q · filed 2021-11-22 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $116.15M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $116.15M 10-Q · filed 2021-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |